Undisclosed IL-17A inhibitor / Sanofi, C4X Discovery - LARVOL DELTA

C4X Discovery receives latest milestone payment from Sanofi (GlobeNewswire) - "C4X Discovery Holdings...announces that it has received a milestone payment of €8 million from Sanofi...reflecting further pre-clinical progress in the ongoing oral IL-17A inhibitor programme. This is the latest milestone payment from a license agreement between the two companies, which was first secured in April 2021. Under the terms of the deal, C4XD is entitled to up to a total of €414 million in upfront, pre-clinical, development, regulatory and commercialisation milestone payments plus royalties on future net sales. Including today’s announcement, C4XD has received a total of €18 million in upfront and pre-clinical payments to date. Under the license, Sanofi is seeking to develop and commercialise an oral therapy for the treatment of inflammatory diseases, a multi-billion-dollar market."

Financing • Immunology • Inflammation